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Abstract
Pyrazinamidase (PncA) activates the first-line antituberculous drug pyrazinamide into pyrazinoic acid. The crystal structure
of the Mycobacterium tuberculosis PncA protein has been determined, showing significant differences in the substrate
binding cavity when compared to the pyrazinamidases from Pyrococcus horikoshii and Acinetobacter baumanii.I nM.
tuberculosis, this region was found to hold a Fe
2+ ion coordinated by one aspartate and three histidines, one of them
corresponding to His57 which is replaced by Asp in Mycobacterium bovis, a species naturally resistant to pyrazinamide. The
binding cavity also contains a Cys138-Asp8-Lys96 motif evocating a cysteine-based catalytic mechanism. Mutants have been
constructed and investigated by kinetic and thermal shift assays, highlighting the importance of protein folding and
thermal stability in the pyrazinamidase activity.
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Introduction
Pyrazinamide (PZA), which is an analogue of nicotinamide, is
an important first-line drug used in the short-course treatment of
tuberculosis. This antibiotic plays a key role in shortening the
duration of antituberculous treatment because of its activity
against the persisting tubercle bacilli at an acidic pH [1]. PZA,
which is a prodrug devoid of significant antibacterial activity, is
metabolized into its active form, pyrazinoic acid (POA), by the
amidase activity of the Mycobacterium tuberculosis nicotinamidase/
pyrazinamidase [2] (referred to as MtPncA), encoded by the pncA
gene [3].
Mutations in pncA represent the major mechanism of PZA
resistance in M. tuberculosis [3–8]. One of the most striking features
of the mutations reported in pncA from clinical isolates resistant to
PZA is their diversity, with hundreds of mutations scattered
throughout the pncA gene, including missense mutations, insertions
and deletions [4,6,9–11]. Determination of susceptibility/resis-
tance of M. tuberculosis to PZA is a cumbersome and difficult task
requiring the use of acidic media that renders very unreliable the
interpretation of the growth readings. Therefore, PCR amplifica-
tion and DNA sequencing of pncA is an approach of interest
because it allows rapid detection of the pncA mutations potentially
involved in PZA resistance. However, a critical point in this
approach is to correctly interpret at the level of the structure/
function relationships of PncA the effects of the mutations detected
by the pncA sequencing, first because of the high degree of diversity
of the mutations that can be found in PncA, and secondly, because
a significant proportion of PZA-susceptible clinical isolates display
amino acid substitutions in PncA that have no significant effect on
the pyrazinamidase activity of the enzyme. Different models of the
three-dimensional structure of PncA of M. tuberculosis were
established with this purpose [12,13]. The first to be reported
was based on the structure of the N-carbamoylsarcosine
amidohydrolase (CSHase), an enzyme harbouring, like PncA,
the isochorismatase domain (PF00857) [12]. Using this model, we
found that the level of activity of PncA mutants correlated with the
location of the mutations with respect to the active site residue
Cys138 involved in the nucleophilic attack of PZA. Du and
colleagues established the crystal structure of the pyrazinamidase
from Pyrococcus horikoshii (PhPncA) [14]. The enzyme was found to
have an active cysteine residue at position 133 in the P. horikoshii
numbering system (Cys138 in MtPncA), as well as a Zn
2+ ion
coordinated by 2 His residues, His54 and His71 (His51 and His71
in MtPncA) and one aspartate residue Asp52 (Asp49 in MtPncA).
Formation of the acylenzyme was suggested to involve the thiolate
form of Cys133 activated by another aspartate, Asp10 (Asp8 in
MtPncA) acting as general base, and stabilized by Lys94 (Lys96 in
MtPncA). A cis-peptide bond was identified between Val128-
Ala129 in PhPncA (Ile133-Ala134 in MtPncA) which contributes
to the formation of an oxyanion hole between the main chain NH
of Cys133 on one hand and the one of Ala129 on the other
(Cys138 and Ala134 in MtPncA, respectively). In PhPncA, the
function of the Zn
2+ ion was suggested to be catalytic through the
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formed between the catalytic cysteine residue and the substrate in
the acylenzyme intermediate. In a more recent publication, the
crystal structure of Acinetobacter baumanii PncA (AbPncA) in
complex with nicotinic acid has been established [15]. The
enzyme was found to be a divalent cation-dependent enzyme with
Fe
2+/Zn
2+ (ratio 1:1) hold on by 3 coordinating residues (Asp54,
His56 and His89). Nicotinic acid was found to be directly tethered
to the ion (assumed to be Zn
2+ in the report), its carboxylate group
being hydrogen-bounded to the main-chain amides of cis-Ala155
and Cys159 forming the oxyanion hole in AbPncA (corresponding
to Ala134 and Cys138 in MtPncA).
Besides these structural studies, Zhang and colleagues charac-
terized the PncA protein from M. tuberculosis at the biochemical
level [16]. MtPncA was found to be a [Mn
2+/Fe
2+]-containing
protein (ratio 1:1). Study of mutants generated by site directed
mutagenesis suggested that residues Asp8, Lys96 and Cys138 were
key residues for catalysis, and Asp49, His57 and His71 for metal
ion binding. Considering the structure of the pyrazinamidase from
P. horikoshii, the only 3D-structure available at the time this study
was conducted, they proposed that His57, which is naturally
replaced by an aspartate residue in the PZA resistant species
Mycobacterium bovis [4], is directly involved in metal binding, a
hypothesis that was not confirmed by structural evidences.
In this report, we describe the crystal structure of the
pyrazinamidase/nicotinamidase of M. tuberculosis at a resolution
of 2.2 A ˚. The three-dimensional structure of the enzyme shows
significant differences when compared to the structures of the
pyrazinamidases from P. horikoshii and A. baumanii, mostly at the
level of the loop carrying residue His57 which was observed in the
M. tuberculosis structure to be involved in coordination of an iron
ion. Comparative kinetics and thermal shift assays (TSA) of
MtPncA mutants obtained by site-directed mutagenesis suggested
that predicting the structure-activity relationships for PncA
mutants should take into account not only the kinetics effects
induced by the mutations, but also their effects on protein folding
and stabilization.
Materials and Methods
Bacterial strains, plasmids and growth condition
Strains of M. tuberculosis H37Rv and M. bovis were from our
laboratory collection. The PZA-resistant clinical strains used in
this study were isolated at Pitie ´ Salpe ˆtrie `re Hospital (Paris, France).
Mycobacterial DNA was extracted from colonies by heat choc
treatment (1 min at 100uC, followed by 1 min at 4uC, five times).
Escherichia coli Novablue and BL21 (DE3) competent cells
(Novagen) were used as host cells for pET29a (Novagen) plasmid
transformation and for expression of the PncA proteins,
respectively. E. coli cells were grown in Luria-Bertani (LB) at
37uC in the presence of kanamycin (30 mg/ml).
Cloning, purification and pyrazinamidase activity assay of
wild-type and mutant PncA proteins
In order to purify PncA on a large scale, the pncA gene of strain
H37Rv of M. tuberculosis was amplified using the amplification
primers pncASCT-HindIII (
59TATAAGCTTTCCTCCTCAG-
GAGCTGCAAACCAA
39)( HindIII site underlined) and pncS-
NdeI(
59GGGGAATTCCATATGCGGGCGTTGATCATC
39)
(NdeI site underlined), and cloned into the HindIII- and NdeI-
restricted sites of the expression vector pET29a. Point mutations
were introduced by site-directed mutagenesis in the pncA gene
cloned in the pET29a vector using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene).
The recombinant plasmids were introduced by transformation
into E. coli BL21 (DE3), which was used as host cell for protein
expression after induction of a 1L culture by IPTG 0.4 mM at
28uC over night. Bacterial cells were pelleted, resuspended in
20 ml of Bis-Tris 40 mM pH 6.0 DTT 1 mM, and lysed by
ultrasonic treatment. The supernatant was applied onto a 2.5- x
10-cm Q Sepharose fast flow column (Pharmacia Co. Ltd.,
Sweden). The fractions containing PncA were eluted by a linear
gradient of 0 to 1M NaCl in Bis-Tris 40 mM pH 6.0,
concentrated with Amicon ultra 15 ml (Millipore) and loaded
onto a gel filtration Superdex 75 (Pharmacia Co. Ltd., Sweden)
previously equilibrated with Bis-Tris 40 mM pH 6.0. Finally the
enzyme was concentrated onto Microcon YM30 (Millipore) to a
final concentration of 20 mg/ml. The experimental molecular
weight was determined by gel filtration to be 22.8 kDa. As the
theoretical molecular weight of PncA is 19.6 kDa, we concluded
that MtPncA is a monomeric protein.
The assay for pyrazinamidase activity was carried out as
previously described [17] using 1 mM of pure enzyme and 2 mM
of PZA. Specific activities were expressed in U.mg
21 using an
extinction coefficient De450 of 6 10
24 mM
21.cm
21 [12].
Thermal shift assay (TSA) of PncA proteins
TSA experiments were carried out as previously described [18]
using a PTC-200 real-time PCR instrument (Bio-Rad). 50 mMo f
protein in BisTris 20 mM pH 6.0 was mixed with 2 ml of 50006
Sypro Orange (Molecular Probes) diluted 1:100 in water. The
samples were heated from 20 to 95uC with a heating rate of 1uC
per minute. Protein thermal unfolding curves were monitored by
detection of changes in fluorescence of the Sypro Orange. The
melting temperature (Tm) was determined by reading the
temperature at which the reaction was half- complete.
Inductively coupled plasma-mass spectrometry (ICP MS)
Inductively coupled plasma-mass spectrometry (ICP MS) was
used for metal-ion identification. Purified PncA protein was
diluted to a final concentration of 5.2 mg/ml. One mL of protein
solution was digested with 500 mL of HNO3 (69–70%) for 4 h at
85uC using a DigiPrep digestion system (SCP, Que ´bec, Canada).
Samples were analyzed by triplicate runs on a ICP MS Agilent
7500ce (Tokyo, Japan) instrument. Total Mg, Fe, Co, Mn and Zn
concentrations were measured using an external calibration curve
determined with reference standards for each ion.
Crystallization and structure determination
PncA crystals were grown in sitting drops against a solution
containing 1.6 M of MgSO4 and 0.1 M of MES at pH 6.6. Drops
(2 ml) consisted in a 1:1 (v/v) mixture of the well and protein
solutions (20 mg/ml in Bis-Tris 40 mM pH 6.0). The crystals were
frozen by a 100 K nitrogen gas stream without cryoprotection
before data collection at the ESRF (European Synchrotron
Radiation Facility, Grenoble, France, ID23-2 beamline Micro-
focus). The crystals belong to the hexagonal space group P6122
with unit cell axes a=b=84.1 A ˚ and c=100 A ˚, with a solvent
content of 52%. The data were processed with XDS [19] and the
structure was obtained by molecular replacement with the
program PHASER [20] using the crystal structure of the
pyrazinamidase/nicotinamidase of Pyrococcus horikoshii (PDB acces-
sion number 1IM5) as search model. Refinement and model
building cycles were performed using CNS [21], Refmac [22], O
[23] and Coot [24]. A summary of the relevant statistics of the
data collection and refinement is given in Table 1. The
coordinates and structure factors of PncA have been deposited
in the Protein Data Bank with the PDB ID code 3PL1.
M. tuberculosis Pyrazinamidase Crystal Structure
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e15785Superposition between the different protein structures were
performed using the secondary structure matching algorithm
SSM [25] as implemented in the program Coot [24]. The figures
were generated using Pymol [26].
Molecular modeling of the PZA-PncA acyl-enzyme
intermediate
The PZA structure was constructed using the module Modeler
in InsightII (Accelerys). Hydrogen atoms were added and the
molecule was energy minimized using CHARMM program [27]
and the force field PARAM22 [28] by using the steepest-descent
algorithm. The PZA-PncA acyl-enzyme intermediate structure
was built using Modeler in InsightII (Accelerys). Briefly, PZA was
first docked into the PncA structure using the Autodock program
[29]. The best docking solution, mostly based on the value of the
Autodock Intermolecular Energy parameter and the reasonable-
ness of the interactions between the ligand and the protein, was
used for the construction of the PZA-PncA acyl-enzyme
intermediate which was further energy-minimized (100 steps)
using the minimization module of CNS [21].
Results
Crystal structure of the M. tuberculosis PncA protein
The crystal structure of PncA was determined to 2.2 A ˚
resolution by molecular replacement using PhPncA as search
model. The asymmetric unit contained a single protein molecule.
The final structure of MtPncA included 185 residues and was
characterized by Rcrystal and Rfree of 19.7% and 24%, respectively
(for details, see Table 1). Only the last C-terminal residue, Ser186,
was not modeled because of the absence of electron density.
The structure of PncA is made of a six-stranded parallel beta-
sheet with helices packed on either side to form an a/b single
domain (Figure 1). Helix a3 bears in its N-terminal part the active
site cysteine residue Cys138. A strong peak was observed in the
Fo-Fc map at the level of residues His51, His57, His71 and Asp49.
Based on the previous report of Zhang et al. [16], we attributed in
a first attempt the couple Mn
2+/Fe
2+ to this density, with an
occupation factor of 50% for each ion. After refinement, the final
B factors for Mn
2+/Fe
2+ were 30/34 A ˚ 2, respectively, which are
values similar to those of the neighboring atoms. The metal ion
present in PncA was finally identified by ICP-MS analysis,
showing that MtPncA contained iron at a concentration of
180 mM for a total protein concentration of 260 mM in the assay.
Low concentrations of zinc and manganese (42 mM and 16 mM,
respectively, for a total protein concentration of 260 mM) were also
detectable. A final refinement considering Fe
2+ as the ion present
in PncA showed that the iron atom was coordinated in a distorted
tetragonal bipyramidal arrangement by (i) the side chains of
residues His51, His71 and two water molecules, HOH220 and
221 in equatorial position, and (ii) the side chains of Asp49 and
His57 in axial position (Figure 1).
Superposition of the PncA structures and description of
the M. tuberculosis PncA active site
Structural alignments revealed a high level of similarity between
the structure of PncA from M. tuberculosis presented in this report
and the two crystal structures of PncA from P. horikoshii and A.
baumanii (rmsds of 0.96 A ˚ and 2.8 A ˚ for 1IM5 and 2WT9,
respectively). However, very marked structural differences were
observed in two regions of PncA. One corresponded to an
insertion of a stretch of 5 amino acids, VDENG, located between
residues Gly108 and Thr114 in MtPncA (data not shown). The
Table 1. Data collection and Refinement Statistics.
Data Collection Statistics PncA
Space group P6122
Cell dimensions a=b=84.1 A ˚,c=1 0 0A ˚
a=b=90u, c=120u
Wavelength (A ˚) 0.9791
Resolution range (A ˚)
a 42.0–2.2 (2.32–2.2)
Number of unique reflections
a 10481 (1260)
Redundancy
a 11.6 (11.5)
Rsym (%)
a 7.8 (49.8)
I/s(I)
a 20.6 (3.4)
Completeness (%)
a 92.9 (72.5)
Refinement Statistics
Rcrystal (%) 19.7
Rfree (%) 24
Number of proteins atoms 1372
Number of solvent atoms
Number of heterogen atom
44
1
r.m.s.d. bond distance (A ˚) 0.02
r.m.s.d. angle (u) 2.1
Average B value (A ˚2)4 5
aValues in parentheses correspond to the high resolution shell.
doi:10.1371/journal.pone.0015785.t001
Figure 1. Ribbon representation of the structure of the M.
tuberculosis PncA protein. The secondary structures, the iron binding
site (Asp49, His51, His57, His71) and the catalytic triad (Cys138, Asp8,
Lys96) are annotated. The iron ion is represented by the orange sphere,
the two water molecules by red spheres.
doi:10.1371/journal.pone.0015785.g001
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to His71 (Figure 2A). Strikingly, this region, which constitutes the
lid of the binding cavity, adopts in MtPncA a conformation
displaying extensive displacements when compared to AbPncA
(local rmsd of 5 A ˚, a large insertion of 13 amino acid residues
being present in AbPncA) and PhPncA (local rmsd of 3 A ˚), in
particular at the level of residue His57 which is located in axial
position relative to the Fe ion in MtPncA, such that its side chain
establishes a strong coordination bond with the metal ion (shown
on Figure 2A). In the structures of PhPncA and AbPncA, the two
residues occupying a positioning equivalent to that of His57 in
MtPncA are Ser60 and Ser62, respectively (see Ser60 on
Figure 2A). Conversely, the two His residues corresponding to
His57 in the sequences of PhPncA and AbPncA (His58 and His60,
respectively) are shifted by 5.2 and 4.4 A ˚, respectively, compared
to the position of the Ca of His57 in MtPncA, such that they
cannot participate in the two former structures to the binding of
the metal ion (see His58 on Figure 2A).
The substrate binding cavity in MtPncA is a small crevice of
approximately 10 A ˚ deep and 7 A ˚ wide, which is delineated on
one side by a catalytic triad made of residues Lys96 at the end of
strand b3, Asp8 at the end of strand b1 and Cys138 at the N-ter
extremity of helice a3 (see Figures 1 and 2B). Asp8 contributes to a
network of 3 H-bonds with the main chain NH of Asp49, the
hydroxyl group of the side chain of Thr47 and the deacylating
water molecule HOH202, respectively. Strikingly, and as opposed
to previous observations made in PhPncA and AbPncA, the side
chain of the key catalytic residue Cys138 in MtPncA was observed
to be oriented not toward the centre of the binding cavity but,
instead, toward the side chain of Lys96 (Figure 2B). On the
opposite part of the active site, the 3 His residues His51, His57 and
His71, together with Asp49, hold the Fe ion on, leaving a lot of
room in the middle of the cavity for PZA binding. Notably, His51
and His71 correspond to the hinge of the loop encompassing
residues 52 to 70 (Figure 2A). This loop, which constitutes a flap
closing the binding cavity, is locked by the third coordination bond
established between His57 and Fe
2+ (Figure 2A). In the most
extended part of this loop, another important residue, Trp68, is
positioned above the catalytic cleft, so that it delineates, together
with His137 and Phe13, the other sides of the binding site
(Figure 2A). Interestingly, despite the extended rearrangements
observed in the 51-71 loop in M. tuberculosis, Trp68 has a highly
conserved positioning in PhPncA, AbPncA and MtPncA (see
Figure 2A for the superimposition of MtPncA and PhPncA). In
MtPncA the positioning of Trp68 is ensured by the main chain
C=O of His57 establishing a direct hydrogen bonding interaction
with the main chain NH of Trp68 (Figure 2B). This interaction is
conserved in PhPncA and AbPncA, both enzymes displaying a
similar H-bond between the main chain NH of the Trp residue
and the main chain C=O of Ser60 and Ser62, respectively (data
not shown). Finally, another interesting feature in the active site of
PncA is the presence of a cis-peptide bond between residues Ile133
and Ala134, which orients the amide nitrogen atom of Ala134
toward the active site centre, so that it forms a potential oxyanion
Figure 2. Detailed description of the active site region in
MtPncA. A Superimposition of the active site regions in MtPncA (in
green) and PhPncA (in red). The Fe2
+ ion is depicted by an orange
sphere, and water molecules by red spheres. The two proteins are
shown in ribbon representation, with the side chains of interest in stick
representation. B Details of the MtPncA active site in ribbon and stick
representation. Hydrogen bonds are represented as black broken lines.
C Modeling of the putative acyl-enzyme intermediate formed between
the drug (PZA) and the side chain of Cys138 in MtPncA.
doi:10.1371/journal.pone.0015785.g002
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this potential oxyanion hole is occupied by a water molecule
(HOH217).
Molecular modeling of the acyl-enzyme complex
The structure of the acyl-enzyme complex formed between
PncA and pyrazinamide has been modeled and is presented on
Figure 2C. According to this model, the acylated side-chain of
Cys138 clearly adopts a conformation in which the side-chain
sulfur atom is reoriented toward the centre of the catalytic cleft.
The carbonyl oxygen atom of PZA is ensconced in the oxyanion
hole, i.e. between the NH-main chain groups of Cys138 and cis-
Ala134. A water molecule, HOH202, lies immediately beneath the
carbonyl carbon atom. This water molecule, which makes H-
bonding interactions with the general base Asp8 on one hand, and
the main chain carbonyl group of Ile133 on the other, is ideally
positioned for nucleophilic attack of the acyl bond (Figure 2C). On
the other side, the 6-membered ring of PZA is embedded between
the three rings provided by residues Trp68, Phe13 and His137,
and the positioning of the substrate is stabilized by one additional
H-bond formed between the nitrogen atom N7 of the six-
membered ring of PZA and the water molecule HOH220 which is
itself bound to the main chain CO of Ala102 and to the Fe
2+ ion.
One can note here that the structure of the acyl-enzyme complex
formed between nicotinamide and MtPncA is nearly identical to
the one obtained with pyrazinamide (data not shown).
Activities of wild-type and mutant proteins from M.
tuberculosis and M. bovis, and thermal shift assay results
Eleven PncA mutants were constructed by site-directed
mutagenesis, over-expressed in E. coli BL21(DE3) and purified in
order to study their thermal stability and their catalytic behavior.
Of the 11 mutants, one contained a phenotypically neutral
substitution, Cys184Ser, introduced far from the active site
residues, at the level of the penultimate residue of the polypeptide
chain on the C-terminal helix a4. The 10 other mutants included
His51Ala, His57Asp and Asp49Gly at the level of the Fe
2+ binding
site, Asp8Leu, Asp8Glu, Lys96Gln, Ala134Val and Cys138Ala in
the catalytic site, and Phe13Leu and Trp68Leu in the PZA
binding cavity.
As expected, the Cys184Ser mutant was produced with a yield
comparable to that of the wild-type enzyme (18.5 versus 27 mg of
pure protein obtained from a 1 litre culture, respectively) (Table 2).
The two proteins also shared similar behavior in kinetic analyses
(specific activity of 22 and 24 U.mg
21, respectively) and in TSA
experiments (Tm =43uC). In both cases, binding of the Sypro-
orange fluorescent probe resulted first in an increase in
fluorescence intensity corresponding to the increase in dye binding
due to the exposition of the buried hydrophobic regions at the
beginning of the unfolding process. After a short transition by a
maximum of fluorescence, this phase was followed by a drop of the
fluorescent signal emitted by the probe due to global destructuring
of the protein when temperature reaches too high values (see
Figure 3).
By contrast, most of the other PncA mutants were found to be
produced at yields up to 19-fold lower than those observed for the
wild-type Pnca protein, the mutant Asp8Leu being completely lost
during the course of the purification process because of protein
precipitation (Table 2). As Asp8Leu precipitated, we constructed
another mutant, Asp8Glu, which was produced at a low yield
(1.4 mg of pure protein per liter of culture). Interestingly, the
Asp8Glu mutation drastically modified the nature of the unfolding
curve obtained by TSA. Indeed, this mutant showed a relatively
high level of fluorescence at low temperatures, i.e. in the 20–30uC
range preceding the initial unfolding phase (Figure 3). Moreover,
the Tm value of the mutant (32uC) was decreased by 11uC when
compared to the wild-type enzyme, and the mutant was
characterized in the kinetic assays by a drastic decrease of PZase
activity (0.020 U/mg) (Table 2).
The other mutations introduced in the active site (Lys96Gln,
Ala134Val, Cys138Ala, Asp49Gly, His51Ala, His57Asp, Trp68
Leu, and Phe13Leu) had very similar effects. Most of the mutants,
except Phe13Leu, showed a marked reduction in the purification
yields (1.8 to 8.4 mg per litre of culture, with an average value of
4.3 mg per litre of culture). On TSA analysis, they displayed
atypical unfolding curves characterized by high fluorescence
intensities at low temperature (increased by 1.5 to 2.5 fold) (see
Figure 3 and Table 2) and Tm values (33 to 39uC) significantly
decreased compared to the wild-type enzyme (43uC) (Table 2).
Mutants harboring the amino acid changes Trp68Leu, Ala134Val,
Asp8Glu, Lys96Gln and Asp49Gly displayed the most marked
effects, in particular Trp68Leu for which the initial unfolding
transition was hardly detectable as the protein underwent
significant unfolding between 30–40uC, which is the range of
temperature usually corresponding to the transition during which
fluorescence raises for the other mutants (Figure 3). For
Ala134Val, the initial unfolding phase was too flat to allow
determination of the midpoint of the unfolding phase. As indicated
by the values of their specific activities, all the mutants were
affected in the PZase activity, with no detectable PZA hydrolysis
for Cys138Ala, Lys96Gln and Asp49Gly, and a very low residual
activity for Ala134Val, His51Ala, His57Asp, Trp68Leu and
Phe13Leu (Table 2).
Discussion
The overall architecture of the pyrazinamidase of M. tuberculosis
is similar to that reported for the other pyrazinamidases of A.
baumanii and P. horikoshii. However, several striking structural
variations that have been specifically detected in the crystal
structure of MtPncA, are of particular note. First, analysis of the
metal ion content of MtPncA by ICP-MS analysis indicated that
the enzyme preferentially contains iron. Thus, our results are
rather in agreement with the previous report of Zhang et al. [16]
Table 2. Biochemical properties of wild-type and mutant
PncA proteins.
PncA
proteins
Yield of
protein (mg)
TSA results
IFI
a Tm
b
Specific
activity
c
Wt
C184S
D8L
D8E
K96Q
A134V
C138A
D49G
27
18.5
pp
d
1.4
6.2
1.8
6.8
1.9
1
0.5
2.3
2.2
2.5
1.5
2.2
43
43
32
35
nd
e
38
33
24
22
0.020
0
0.010
0
0
H51A
H57D
W68L
F13L
2.7
2.4
8.4
17
1.9
1.5
2.5
1.9
35
39
nd
e
35
0.25
0.005
0.005
0.02
aIFI, initial fluorescence intensity, expressed comparatively to that of the
wild-type enzyme set to 1.
bTm in uC.
cSpecific activities expressed in U.mg
21.
dpp, not determinable because of protein precipitation.
end, not determinable.
doi:10.1371/journal.pone.0015785.t002
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and manganese with a molar ratio 1:1, as opposed to what was
speculated from the study of the pyrazinamidase of P. horikoshii
which hypothesized that the metal ion present in PncA is a zinc
playing a direct catalytic role by promoting a hydroxyl ion
involved in hydrolysis of the drug [14]. The latter assumption
seems to be definitively ruled out considering the fact that the
metal ion in MtPncA is located too far from the active site cysteine
residue (Cys138) to be capable to contribute directly to PZA
hydrolysis through the activation of a water molecule. However, it
cannot be excluded that manganese or zinc can also occupy the
metal binding site in MtPncA, as recently suggested in a study that
identified the presence of manganese in MtPncA by EPR
spectroscopy [30] and as observed in the present study showing
the presence of low amounts of zinc and manganese in MtPncA.
The second striking structural feature observed in MtPncA
corresponds to the very peculiar conformation of the 51–71 loop
forming a protrusion that occludes the mouth of the binding
cavity. Interestingly, the most significant structural variations
observed between MtPncA on one hand and PhPncA and
AbPncA on the other, are concentrated in this part of the protein.
One of the most crucial structural elements in this loop appears to
be the specific positioning of residue His57 which is directly
involved in the coordination of the Fe
2+ ion. Thus, this residue
undoubtedly constitutes an essential element of the scaffolding of
the loop by ensuring a covalent stabilization at the level of residue
57 which, itself, is involved in the positioning of Trp68 (direct H-
bonding interaction between the main chain C=O of His57 and
the main chain NH of Trp68) and of Ser66 (indirect interaction
with the side chain of His57 via the water molecule HOH230) (see
Figure 2B). The structural bases for the specific conformation of
loop 51–71 at the level of His57 in M. tuberculosis, which is not
involved in protein-protein interactions in the crystal packing, are
likely related to the specific amino acid sequence found in the 51–
71 region around His57. Notably, in PhPncA and AbPncA, the
motif in this region is D49WH51PXXH55, (where X represents a
non-conserved residue) whereas in MtPncA the sequence is
D49FH51XXPXXH57, such that an insertion of 2 additional
residues is specifically observed in MtPncA between His51 and the
PXXH57 motif. This insertion in MtPncA allows His57 to be
shifted toward the metal binding site and correctly positioned to
participate in the coordination of the Fe
2+ ion. Taken altogether,
these observations readily account for the fact that M. bovis, which
possesses a histidine to aspartate substitution in position 57,
produces an inactive PncA protein and is, consequently, naturally
resistant to PZA [4].
On the basis of the MtPncA structure reported here, the
addition-elimination mechanism previously proposed for the
pyrazinamidase of A. baumanii [15] likely applies in M. tuberculosis.
According to this mechanism, the binding of the drug would be
mostly ensured by (i) the hydrogen bonding interaction formed
between the pyridyl nitrogen atom of PZA and the water molecule
Figure 3. Unfolding of MtPncA and various mutants monitored in the presence of SYPRO orange. The proteins were gradually heated
and the unfolding process was monitored by detection of the charges of fluorescence of the dye reporter that binds preferentially to the unfolded
proteins [18]. The fluorescence intensities (Y axis) are measured according to the temperature (X axis, in uC).
doi:10.1371/journal.pone.0015785.g003
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2+ ion and (ii) the strong
interaction of the carbonyl-oxygen atom of PZA in the Ala134-
Cys138 oxyanion hole. In a second stage, the nucleophilic thiolate
form of Cys138, promoted by Asp8, would attack the carbonyl
carbon atom of PZA, resulting in the release of ammonia and
formation of the acyl-enzyme intermediate shown on Figure 2C.
The latter compound would be finally hydrolysed by the water
molecule HOH202 ideally positioned and activated by the general
base Asp8 to perform the final hydrolytic step.
A major new finding in the study of the PncA mutants presented
in this report is the essential contribution of the studied residues
not only to catalysis but also to protein folding and thermal
stability. For all the studied mutants (excluding Cys184Ser which
behaved like the wild-type enzyme), total loss or very low residual
levels of PZase activity was observed whatever was their
contribution in MtPncA (catalytic triad for Cys138Ala, Asp8Glu
and Lys96Gln, formation of the oxyanion hole for Ala134Val, Fe
coordination for Asp49Gly, His51Ala and His57Asp, substrate
binding for Trp68Leu and Phe13Leu), a result that confirms their
importance in the PZase activity of MtPncA. The results of the
TSA assay indicated that most of the mutants also exhibited
drastic changes in their unfolding curves compared to the wild-
type MtPncA protein, most particularly Asp8Glu, Lys96Gln,
Ala134Val, Asp49Gly and Trp68Leu (Figure 3). The major effect
induced by these mutations corresponded to a marked increase in
the initial fluorescence values and, for the two mutants Ala134Val
and Trp68Leu, to the absence of unfolding transition at the
beginning of heating (30–40uC). These observations are consistent
with the hypothesis that such mutants would display a significant
degree of unfolding at 20uC, at least in the region of the binding
site, which would increase the accessibility of the fluorescent
reporter to hydrophobic regions of the protein prior to thermal
treatment, as suggested in a recent report applying the thermal
shift assay to the investigation of mitotic kinesins [31]. In addition,
these mutants exhibited significant decrease in thermal stability, as
reflected by Tm values not determinable for Ala134Val and
Trp68Leu, and decreased by 8 to 11uC for Asp8Glu, Asp49Gly
and Lys96Gln, corroborating the idea that these mutations are
associated with significant effects on the integrity of the 3D
structure of PncA. Regarding the 4 remaining mutants, His51Ala,
His57Asp, Cys138Ala and Phe13Leu, their consequences on
unfolding curves and Tm shifts were less pronounced, suggesting
that these mutations have more limited effects on folding and
stability of MtPncA.
In conclusion, the crystal structure of the pyrazinamidase from
M. tuberculosis described here has unveiled important structural
features of the enzyme and so, represents a valuable tool to
decipher the structure-function relationships and investigate the
molecular mechanisms of resistance to PZA stemming from the
point mutations identified in clinical isolates. In particular, it
highlights the important role played by the Fe
2+ ion and His57 for
local stabilisation of the 51–71 loop, accounting for the production
of defective PncA protein in M. bovis which naturally possesses an
aspartate at this position. Finally, it highlights the underestimated
importance of protein folding and thermal stability in PZase
activity of the PncA mutants produced in clinical isolates, a
parameter which has to be taken into account to fully understand
resistance to PZA.
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